Suppression of eIF4E expression by L-asparaginase

Acta Haematologica

Volumn 123, Issue 4, 2010, Pages 215-219

  Suto, Hiroko ^a   Yasuda, Hajime ^a   Isobe, Yasushi ^a   Sasaki, Makoto ^a   Imai, Hidenori ^a   Tsutsui, Miyuki ^a   Oshimi, Kazuo ^a   Komatsu, Norio ^a   Sugimoto, Koichi ^a  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE; ASPARTATE AMMONIA LIGASE; DOXORUBICIN; ELONGATION FACTOR 1ALPHA; ELONGATION FACTOR 2; INITIATION FACTOR 4A; INITIATION FACTOR 4E; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN KINASE B; PROTEIN MCL 1; PROTEIN S6; RAPAMYCIN; S6 KINASE;

APOPTOSIS; ARTICLE; B CELL LYMPHOMA; CHEMOSENSITIVITY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG TARGETING; ENZYME ACTIVATION; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; NICK END LABELING; NK T CELL LYMPHOMA; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS INHIBITION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; ASPARAGINASE; CELL TRANSFORMATION, NEOPLASTIC; EUKARYOTIC INITIATION FACTOR-4E; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; JURKAT CELLS; NEOPLASM PROTEINS; NEOPLASMS;

EID: 77951217652     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000313362     Document Type: Article

References (20)

1. Lazaris-Karatzas A, Montine KS, Sonenberg N: Malignant transformation by a eukaryotic initiation factor subunit that binds to mRNA 5′ cap. Nature 1990; 345: 544-547.
2. Ruggero D, Montanaro L, Ma L, Xu W, Londei P, Cordon-Cardo C, Pandolfi PP: The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis. Nat Med 2004; 10: 484-486.
3. Rosenwald IB, Chen JJ, Wang S, Savas L, London IM, Pullman J: Upregulation of protein synthesis initiation factor eIF-4E is an early event during colon carcinogenesis. Oncogene 1999; 18: 2507-2517.
4. Li BD, Liu L, Dawson M, De Benedetti A: Overexpression of eukaryotic initiation factor 4E (eIF4E) in breast carcinoma. Cancer 1997; 79: 2385-2390.
5. Wang S, Rosenwald IB, Hutzler MJ, Pihan GA, Savas L, Chen JJ, Woda BA: Expression of the eukaryotic translation initiation factors 4E and 2alpha in non-Hodgkin's lymphomas. Am J Pathol 1999; 155: 247-255.
6. Gingras AC, Raught B, Sonenberg N: eIF4 initiation factors: effectors of mRNA recruitment to ribosomes and regulators of translation. Annu Rev Biochem 1999; 68: 913-963.
7. Graff JR, Konicek BW, Carter JH, Marcusson EG: Targeting the eukaryotic translation initiation factor 4E for cancer therapy. Cancer Res 2008; 68: 631-634.
8. De Benedetti A, Graff JR: eIF-4E expression and its role in malignancies and metastases. Oncogene 2004; 23: 3189-3199.
9. Pui CH, Evans WE: Treatment of acute lymphoblastic leukemia. N Engl J Med 2006; 354: 166-178.
10. Yong W, Zheng W, Zhu J, Zhang Y, Wang X, Xie Y, Lin N, Xu B, Lu A, Li J: L -asparaginase in the treatment of refractory and relapsed extranodal NK/T-cell lymphoma, nasal type. Ann Hematol 2009; 88: 647-652.
11. Jaccard A, Petit B, Girault S, Suarez F, Gressin R, Zini JM, Coiteux V, Larroche C, Devidas A, Thiéblemont C, Gaulard P, Marin B, Gachard N, Bordessoule D, Hermine O: L - asparaginase-based treatment of 15 Western patients with extranodal NK/T-cell lymphoma and leukemia and a review of the literature. Ann Oncol 2009; 20: 110-116.
12. Yamaguchi M, Suzuki R, Kwong YL, Kim WS, Hasegawa Y, Izutsu K, Suzumiya J, Okamura T, Nakamura S, Kawa K, Oshimi K: Phase I study of dexamethasone, methotrexate, ifosfamide, L -asparaginase, and etoposide (SMILE) chemotherapy for advancedstage, relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma and leukemia. Cancer Sci 2008; 99: 1016-1020.
13. Ando M, Sugimoto K, Kitoh T, Sasaki M, Mukai K, Ando J, Egashira M, Schuster SM, Oshimi K: Selective apoptosis of natural killer- cell tumours by L -asparaginase. Br J Haematol 2005; 130: 860-868.
14. Clarkson B, Krakoff I, Burchenal J, Karnofsky D, Golbey R, Dowling M, Oettgen H, Lipton A: Clinical results of treatment with E. coli L -asparaginase in adults with leukemia, lymphoma and solid tumors. Cancer 1970; 25: 279-305.
15. Fine BM, Kaspers GJ, Ho M, Loonen AH, Boxer LM: A genome-wide view of the in vitro response to L -asparaginase in acute lymphoblastic leukemia. Cancer Res 2005; 65: 291-299.
16. Stams WAG, den Boer ML, Beverloo B, Meijerrink JPP, Stigter RL, van Wering ER, Janka- Schaub GE, Slater R, Pieters R: Sensitivity to L -asparaginase is not associated with expression levels of asparagine synthetase in t(12; 21) + pediatric ALL. Blood 2003; 101: 2743-2747.
17. Iiboshi Y, Papst PJ, Hunger SP, Terada N: L - Asparaginase inhibits the rapamycin-targeted signaling pathway. Biochem Biophys Res Commun 1999; 260: 534-539.
18. Wendel HG, De Stanchina E, Fridman JS, Malina A, Ray S, Kogan S, Cordon-Cardo C, Pelletier J, Lowe SW: Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 2004; 428: 332-337.
19. Wendel HG, Silva RL, Malina A, Mills JR, Zhu H, Ueda T, Watanabe-Fukunaga R, Fukunaga R, Teruya-Feldstein J, Pelletier J, Lowe SW: Dissecting eIF4E action in tumorigenesis. Genes Dev 2007; 21: 3232-3237.
20. Ruggero D, Sonenberg N: The Akt of translational control. Oncogene. 2005; 24: 7426-7434.